Rapport Therapeutics, Inc.
RAPP
$27.62
-$0.22-0.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.40% | -0.72% | -11.09% | -20.44% | -13.93% |
| Total Depreciation and Amortization | 3.52% | 1.59% | 3.28% | -6.15% | 18.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.74% | 15.19% | 19.05% | 2.08% | 185.00% |
| Change in Net Operating Assets | -2.46% | 209.73% | -678.29% | -132.29% | 381.13% |
| Cash from Operations | -41.43% | 30.34% | -23.88% | -40.09% | 12.00% |
| Capital Expenditure | -26.12% | -509.09% | 92.44% | -28.76% | -61.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -207.47% | -350.43% | 6.08% | -33.69% | 160.79% |
| Cash from Investing | -207.04% | -351.27% | 7.44% | -34.13% | 160.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.89% | -- | -100.00% | -14.29% | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 200.00% | -- | -- | -- |
| Cash from Financing | -99.89% | 429,517.46% | -1,360.00% | -28.57% | 100.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -201.23% | 7,837.17% | -417.52% | -95.43% | 124.69% |